Interleukin-1- Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19.

Gupta, Akash; Chun, Hyung J

Gupta, Akash; Chun, Hyung J.

Gupta A; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.
Chun HJ; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.

Front Immunol ; 12: 693085, 2021.

Article in English | MEDLINE | ID: covidwho-1305647

Subject(s)

COVID-19/metabolism; Cytokine Release Syndrome/metabolism; Interleukin-1 Receptor-Associated Kinases/metabolism; Protein Kinase Inhibitors/therapeutic use; SARS-CoV-2/physiology; Animals; Antibodies, Monoclonal/therapeutic use; Cytokine Release Syndrome/drug therapy; Cytokines/metabolism; Drug Synergism; Humans; Immunomodulation; Interleukin-1 Receptor-Associated Kinases/genetics; Pandemics; COVID-19 Drug Treatment

Keywords

COVID-19; Cytokine release syndrome (CRS); cytokine; immunomodulator; irak4

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Protein Kinase Inhibitors / Interleukin-1 Receptor-Associated Kinases / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Limits: Animals / Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.693085

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google